Searchable abstracts of presentations at key conferences in endocrinology

ea0022p177 | Clinical case reports and clinical practice | ECE2010

Pursuit endocrinology – perceptions, understanding and reactions of students undertaking internal medicine training regarding endocrinology

Kalra Sanjay , Agrawal Navneet , Unnikrishnan AG , Sahay Rakesh , Kalra Bharti

This paper studies the attitudes of postgraduate medical students towards endocrinology and diabetology as a career.Fifty post graduate students, pursuing residency in internal medicine, at various colleges throughout India, were requested to fill up a pre-tested, five point Likert scale questionnaire designed to assess their likings for various branches and aspects of medicine.The average age of the respondents was 27 years, with ...

ea0020p358 | Diabetes and Cardiovascular | ECE2009

Biphasic insulin aspart 30/70 improves glycaemic control in patients with type 2 diabetes: clinical practice experience from Indian subgroup of the IMPROVE study™

Unnikrishnan AG , Shah Siddharth , Asirvatham Arthur , Chakkarwar Praful , Moharana Ashok , Kapoor Dheeraj

Aims & objectives: IMPROVE™ is a 6-month, multi-national, prospective, observational study, assessing the safety and efficacy of biphasic insulin aspart 30/70 (BiAsp 30) in patients with type 2 diabetes.Methods: We present the efficacy data from the Indian cohort of IMPROVE study. A total of 17 995 subjects entered the study and 16 942 subjects completed the study. BiAsp 30 was initiated and dose was adjusted at the physician’s discretion, ...

ea0020p386 | Diabetes and Cardiovascular | ECE2009

NovoMix30® reduces hypoglycemic events with favorable weight change in poorly controlled type 2 diabetes patients: results from Indian cohort of IMPROVE Study

Kalra Sanjay , Unnikrishnan AG , Kumar Ajay , Moharana Ashok , Prusty Vinay , Baruah Manash

Objective: IMPROVE study was designed to assess the safety and effectiveness of NovoMix30® in type 2 diabetes subjects under normal clinical practice conditions.Methods: This large multi-national, open label, prospective, 6 month long observational study captured data for above 50 000 patients started on NovoMix30® with/without oral anti-diabetic drugs (OADs)/other insulin. This paper analyses safety data of 17 995 patient...